P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC
- Immunotherapy P2.01-001 – P2.01-004
- EGFR MT P2.01-005 – P2.01-024
- ALK P2.01-025 – P2.01-029
- Clinical Care of Lung Cancer P2.01-030 – P2.01-050
- Chemotherapy Developments P2.01-051 – P2.01-066
- Meta Analyses and Trial Conduct P2.01-067 – P2.01-069
- EGFR WT, Angiogenesis, OMD P2.01-070 – P2.01-080
- New Targets P2.01-081 – P2.01-085
- Trials in Progress P2.01-086 – P2.01-102

P2.02 TREATMENT OF LOCALIZED DISEASE – NSCLC
- Quality/Prognosis/Survival P2.02-001 – P2.02-016
- Surgery P2.02-017 – P2.02-031
- Chemotherapy in Early Stage Disease P2.02-032 – P2.02-035
- Radiation P2.02-036 – P2.02-041

P2.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC
- Surgery P2.03-001 – P2.03-010
- Chemoradiation P2.03-011 – P2.03-020
- Radiation P2.03-021 – P2.03-030
- Other P2.03-031 – P2.03-038

P2.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
- EGFR P2.04-001 – P2.04-043
- Novel Targets P2.04-044 – P2.04-057
- Immunology and Microenvironment P2.04-058 – P2.04-081
- Liquid Biopsies P2.04-082 – P2.04-096
- Other Resistance (non-EGFR, non-ALK) P2.04-097 – P2.04-109

P2.05 PREVENTION AND TOBACCO CONTROL
- Prevention and Tobacco Control P2.05-001 – P2.05-011

P2.06 SCREENING AND EARLY DETECTION
- CT Screening Programs and Imaging P2.06-001 – P2.06-006
- Biomarkers P2.06-007 – P2.06-013
- Risk, Health Care Delivery, Miscellaneous, P2.06-014 – P2.06-020
Case Reports and Series

- Diagnostic Workup P2.06-021 – P2.06-026
- Prognostic Markers P2.06-027 – P2.06-029

P2.07 SMALL CELL LUNG CANCER

- Biology P2.07-001 – P2.07-004
- Extensive Disease P2.07-005 – P2.07-011
- Limited Disease P2.07-012 – P2.07-015
- Prognosis, Epidemiology and Other P2.07-016 – P2.07-018

P2.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES

- Mesothelioma P2.08-001 – P2.08-016
- Other Thoracic Malignancies P2.08-017 – P2.08-029
- Thymoma P2.08-030 – P2.08-035

P2.09 NURSING AND ALLIED PROFESSIONALS

- Nursing and Allied Professionals P2.09-001 – P2.09-006

P2.10 ADVOCACY

- No posters on Tuesday, September 8, 2015

P2.11 PALLIATIVE AND SUPPORTIVE CARE

- Palliative and Supportive Care P2.11-001 – P2.11-015

P2.12 COMMUNITY PRACTICE

- No posters on Tuesday, September 8, 2015
Tuesday, September 8, 2015

**Poster Setup Time:** 08:30 – 09:30  
**Poster Take Down Time:** 16:45 – 18:30  
(Posters not taken down by 18:30 will be discarded by management)

**PRESENTING AUTHOR STAND BY TIME**

Time in which Poster Presenters remains at his/her poster board and is available to discuss their research personally with interested delegates.  
09:45 – 10:45 and 15:45 – 16:45 (Networking Breaks)

**P2.01 TREATMENT OF ADVANCED DISEASE NSCLC**

**P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC - IMMUNOTHERAPY**

**P2.01-001:**  
**Dendritic Cells: Cytokine-Induced Killer Cells Therapy in Advanced Non-Small Cell Lung Cancer: A Case Report of an Aggressive Tumor Relapse**  
Francisco III M. Heralde, Philippines

**P2.01-002:**  
**Immunotherapy as an Effective Treatment Option in the Metastatic NSCLC in Spite of PD-1 or PDL-1 Inhibition and Line of Therapy**  
Jesús Corral, Spain

**P2.01-003:**  
**T-Cytotoxic Specific Immunotherapy in NSCLC with Brain Metastases**  
*NCT00104780*  
John Nemunaitis, USA

**P2.01-004:**  
**Oncologists' Comprehension and Beliefs Surrounding Cancer Immunotherapy in Advanced NSCLC**  
Tara Herrmann, USA

**P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC – EGFR MT**

**P2.01-005:**  
**Relationship between Icotinib Exposure and Clinical Outcome in Chinese ANSCLC**  
Jun Ni, China

**P2.01-006:**  
**Continuing EGFR-TKI in Combination with Regional Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR(+) Non-Small Cell Lung Cancer**  
Jie Zhang, China
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.01-007</td>
<td>Prognostic Factors including EGFR Status in Advanced Lung Adenocarcinoma Patients</td>
<td>Shunsaku Hayai, Japan</td>
</tr>
<tr>
<td>P2.01-008</td>
<td>Efficacy and Tolerability Analysis of Icotinib in EGFR Mutation-Positive and Unknown Advanced NSCLC Patients from Eastern Coastal China</td>
<td>Xiaochun Zhang, China</td>
</tr>
<tr>
<td>P2.01-009</td>
<td>EGFR Mutation and Brain Metastasis in Patients with Non Small Cell Lung Cancer</td>
<td>Eun Kyung Cho, South Korea</td>
</tr>
<tr>
<td>P2.01-010</td>
<td>Early Radiographic Response to TKI in Non Small Cell Lung Cancer with EGFR Mutations</td>
<td>Óscar Juan Vidal, Spain</td>
</tr>
<tr>
<td>P2.01-011</td>
<td>Relationship between EGFR Mutation Status and Response to Specific Chemotherapeutic Agents in Patients with Stage IV Non-Small Cell Lung Cancer</td>
<td>Vinicius Ernani, USA</td>
</tr>
<tr>
<td>P2.01-012</td>
<td>Clinical Implications of Isolated Bone Failure without Systemic Disease Progression During EGFR-TKI Treatment</td>
<td>Ji An Hwang, South Korea</td>
</tr>
<tr>
<td>P2.01-013</td>
<td>Association of PK/PG with Toxicity of Gefitinib in Patients with Advanced NSCLC</td>
<td>Takashi Hirose, Japan</td>
</tr>
<tr>
<td>P2.01-014</td>
<td>EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer</td>
<td>Kazumi Nishino, Japan</td>
</tr>
<tr>
<td>P2.01-015</td>
<td>The Management of Brain Metastases in Patients with EGFR Mutated Advanced Non-Small Cell Lung Cancer</td>
<td>Noelle O'Rourke, United Kingdom</td>
</tr>
<tr>
<td>P2.01-016</td>
<td>BPI-7701, a Covalent Mutant-Selective EGFR Inhibitor, Inhibits the Growth of NSCLC Lines with EGFR Activating and T790M Resistance Mutations</td>
<td>Victoria L. Wilde, USA</td>
</tr>
<tr>
<td>P2.01-017</td>
<td>Genetic Variations in the EGFR Gene Predicts Outcome in Advanced NSCLC Patients Treated with Erlotinib</td>
<td>Anne Winther Larsen, Denmark</td>
</tr>
<tr>
<td>P2.01-018</td>
<td>Baseline Lymphocyte-Monocyte Ratio Is a Prognostic Marker in EGFR Mutant NSCLC Patients Receiving First Line EGFR TKIs</td>
<td>Yu-Mu Chen, Taiwan</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Author</td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>P2.01</td>
<td>Effect of EGFR Mutation Status on Graded Prognostic Assessment for Non-Small Cell Lung Cancer and Brain Metastases</td>
<td>Cheng Nang Leong</td>
</tr>
<tr>
<td>P2.01</td>
<td>Clinical Differences of EGFR Mutations in Exon 19 and 21 in Clinical Course of Non-Small Cell Lung Cancer Patients</td>
<td>Tae Won Jang</td>
</tr>
<tr>
<td>P2.01</td>
<td>Non-Inferior Progression Free Survival in NSCLC Patients Sensitive to EGFR TKI Receiving Low Dose versus Regular Dose of Gefitinib or Erlotinib</td>
<td>Chun-Ming Tsai</td>
</tr>
<tr>
<td>P2.01</td>
<td>BMI as Factor Predicting the Efficacy of Gefitinib in NSCLC with EGFR Mutation</td>
<td>Wang Ziping</td>
</tr>
<tr>
<td>P2.01</td>
<td>Intercalated Therapy with Gemcitabine, Cisplatin and Erlotinib May Be Superior to TKI Alone for Patients with Advanced EGFR Mutated NSCLC</td>
<td>Matjaz Zwitter</td>
</tr>
<tr>
<td>P2.01</td>
<td>An ENSURE Extension Study to Evaluate 2nd Line Erlotinib and Gemcitabine/Cisplatin Cross-Over Treatment for EGFR-Mutant Chinese NSCLC Patients</td>
<td>Yi-Long Wu</td>
</tr>
</tbody>
</table>

**P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC – ALK**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.01</td>
<td>Crizotinib in Advanced ALK-Positive NSCLC - A Retrospective Multicenter Study in the Slovak Republic</td>
<td>Peter Berzinec</td>
<td>Slovakia</td>
</tr>
<tr>
<td>P2.01</td>
<td>Proactive Management of Potential Gastrointestinal Adverse Reactions with Ceritinib in Patients with Advanced ALK+ NSCLC</td>
<td>Eric Schaefer</td>
<td>USA</td>
</tr>
<tr>
<td>P2.01</td>
<td>Responses to Crizotinib in Six Lung Adenocarcinoma Patients of ALK IHC-Positive and FISH-Negative</td>
<td>Di Ma</td>
<td>China</td>
</tr>
<tr>
<td>P2.01</td>
<td>Neoadjuvant Crizotinib and Surgical Resection of Two Stage IIIA Lung Adenocarcinomas with Anaplastic Lymphoma Kinase Gene Rearrangement</td>
<td>Shaolei Li</td>
<td>China</td>
</tr>
<tr>
<td>P2.01</td>
<td>Physician Decision-Making on Modifying or Discontinuing Crizotinib in ALK+ NSCLC: A Survey of US Physicians</td>
<td>Edmond Bendaly</td>
<td>USA</td>
</tr>
</tbody>
</table>
P2.01-030: Challenging Diagnosis of Adenocarcinoma of the Lung Confirmed by Molecular Analysis: A Clinical Case
Robert El-Maraghi, Canada

P2.01-031: Characteristics of Squamous Cellular Carcinoma Patients In "Colombian Coffee Zone"
Jaime A. Echeverri F, Colombia

P2.01-032: Patterns of Care in Long Term Survivors (> 3 Years) in Advanced NSCLC- Retrospective Analysis of 30 Patients from a Single Institute
Indibor S. Yengkhom, India

P2.01-033: Patients with Advanced NSCLC Requiring Inpatient Oncology Consultation
Joanna Gotfrit, Canada

P2.01-034: Predictive Factors of Brain Metastases Development in Non-Small Cells Lung Cancer
Martin E. Richardet, Argentina

P2.01-035: The Survival Effect of Resection of Cranial Metastatic Lesions in Patients with Lung Cancer
Türkkan Evrensel, Turkey

P2.01-036: Long Term Survival of Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents
Doru Paul, USA

P2.01-037: Genomic Alterations of KRAS, EGFR, and ALK in Patients with Non-Small Cell Lung Cancer, Single Institution Experience
Yi-Hung Carol Tan, USA

P2.01-038: Prognostic Factors for Brain Metastasis in Non-Small Cell Lung Cancer
Narjust Duma, USA

P2.01-039: Clinicopathological Factors in Non-Small Cell Lung Cancer Patients with Bone Metastases
Ahmet Bilici, Turkey

P2.01-040: Survival Gains From Systemic Therapy in Advanced Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities
Joshua A. Roth, USA

P2.01-041: MD Anderson Oncology Expert AdvisorTM System (OEATM): A Cognitive Computing Recommendations Application (App) for Lung Cancer
George R. Simon, USA

P2.01-042: Cost-Effectiveness of Afatinib vs. Erlotinib in the 1st-Line Treatment of Metastatic NSCLC Patients with EGFR Exon 19 Deletion Mutations
Rohit Borker, USA

P2.01-043: Lung Cancer Radiotherapy - Current Patterns of Practice in Australia and New Zealand
Jeremy D. Ruben, Australia

P2.01-044: EGFR-TKIs as Second-Line Treatment of Patients with NSCLC with or without Activating EGFR Mutation as Assessed by Sensitive PNA Clamping Method
Young-Chul Kim, South Korea

P2.01-045: Clinical Experience on Treatment of Advanced Lung Adenocarcinoma With Unknown EGFR Gene Status From a Tertiary Care Center in China
Nong Xu, China

P2.01-046: Making the Diagnosis of Cardiac Tamponade in Lung Cancer Patients
Pooja Ghatalia, USA

P2.01-047: Fibrobronchoscopic Cryorecanalization for Unresectable Secondary Malignant Tumors of the Trachea and Main Bronchi
Qianli Ma, China

P2.01-048: Real-Life 2-Year Therapeutic Strategies in the Management of Metastatic Non-Small-Cell Lung Cancers: The ESCAP Study
Didier Debieuvre, France

P2.01-049: Surgical Treatment Results of T4 Lung Cancer Invading Mediastinum
Masayuki Tanahashi, Japan

P2.01-050: Influence of Maintenance Therapy on Incidence of 2nd Line Therapy and OS in NSCLC IV
Frank Griesinger, Germany

P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC – CHEMOTHERAPY DEVELOPMENTS

P2.01-051: Determinants of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients
Jose Belderbos, Netherlands

P2.01-052: Augmentation of NAD+ by NQO1 Activation Attenuates Cisplatin-Mediated Hearing Impairment
Seihoon Yang, South Korea

P2.01-053: The Role of Systemic Therapy in Sarcomatoid Carcinoma of the Lung
Nagla Abdel Karim, USA

P2.01-054: Continuation Maintenance Therapy of Pemetrexed and Renal Toxicities
Teppei Yamaguchi, Japan
P2.01-055: Prospective Study of UGT1A1*27 Gene Polymorphism for Irinotecan Therapy: Result of Lung Oncology Group in Kyushu (LOGiK1004B)
Minoru Fukuda, Japan

P2.01-056: Thyroid Transcription Factor 1 (TTF1) as a Possible Predictive Biomarker for Pemetrexed-Based Chemotherapy in Non-Squamous NSCLC
Xabier Mielgo Rubio, Spain

P2.01-057: Serum Mass-Spectrometry Test in First-Line Advanced Non-Small Cell Lung Cancer Patients Treated with Standard Chemotherapy Regimens
Francesco Grossi, Italy

P2.01-058: Factors Predicting Long Duration of Pemetrexed Maintenance Therapy: A Retrospective Cohort of 65 Patients
Maurice Pérol, France

P2.01-059: Does Pemetrexed/Platinum Fit All Patients with Non-Squamous Non-Small Cell Lung Cancer? A Retrospective Study of Clinical Factors and Outcomes
Junichi Shimizu, Japan

P2.01-060: Biweekly Irinotecan/Bevacizumab in Heavily Treated Advanced NSCLC and Survival According to TIMP1 and EGFR Expression
Leonardo Rojas, Colombia

P2.01-061: COX-2 Expression Does Not Predict Outcome of Celecoxib in Addition to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer
Bengt Bergman, Sweden

P2.01-062: Efficacy and Safety of Weekly Albumin-Bound Paclitaxel for Non-Small-Cell Lung Cancer Patients Who Have Failed ≥ 2 Prior Systemic Regimens
Jie Wang, China

P2.01-063: Dynamic Change of Fatigue for East-Asian Patients in the JMEN Trial
Li Zhang, China

P2.01-064: A Randomized Phase II Trial of ERCC1 and RRM1 Expression-Based Chemotherapy versus Docetaxel/Carboplatin in Advanced Non-Small Cell Lung Cancer
Su Jin Heo, South Korea

P2.01-065: nab-Paclitaxel + Carboplatin in Advanced NSCLC: Analysis of Age and Renal Function
Corey J. Langer, USA

P2.01-066: A Prospective, Randomized, Multicenter, Phase III Study, Comparing rhTPO with rhIL-11 Treating CIT - An Interim Analysis (NCT02344979)
Shun Lu, China
**P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC – META ANALYSES AND TRIAL CONDUCT**

**P2.01-067:** Quality in Lung Cancer Care: The Victorian Lung Cancer Registry Pilot Initial Report  
Rob Stirling, Australia

**P2.01-068:** Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis  
Mukesh Kumar, USA

**P2.01-069:** Design and Stratification for Phase III Trials in First-Line Non-Small Cell Lung Cancer  
Takefumi Komiya, USA

**P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC – EGFR WT, ANGIGENESES, OMD**

**P2.01-070:** Serum Albumin in Patients with Advanced-Stage NSCLC Treated with Erlotinib  
Ondrej Fiala, Czech Republic

**P2.01-071:** TULUNG REGISTRY: Data Analysis of Patients with Non-Squamous NSCLC Treated with Bevacizumab in the Czech Republic  
Libor Havel, Czech Republic

**P2.01-072:** A Phase II Study of Carboplatin/Pemetrexed/Bevacizumab Followed by Bevacizumab/Erlotinib Maintenance for NonSq-NSCLC with Wild-Type EGFR  
Hiroshi Yokouchi, Japan

**P2.01-073:** Impact of Prophylactic Doxycycline (Doxy) on Maintaining Planned Dosing of Dacomitinib (D) an Irreversible panHER Inhibitor  
Diana Gernhardt, USA

**P2.01-074:** Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer  
Hiroyuki Minemura, Japan

**P2.01-075:** Bevacizumab with Docetaxel or S-1 in Non-Squamous NSCLC (HANSHIN 0110)  
Motoko Tachihara, Japan

**P2.01-076:** Clinical Study of Anti-Angiogenesis Therapy Combined with Neo-Adjuvant Chemotherapy on NSCLC Patients in Phase IIIa (N2)  
Xiao-liang Zhao, China

**P2.01-077:** A Phase 1b Trial of the Combination of Capecitabine and Erlotinib in Advanced Lung Cancer  
Rajiv Kumar, United Kingdom

**P2.01-078:** Concurrent Thoracic Radiotherapy and Tyrosine Kinase Inhibitors for Wild-Type EGFR Patients with Locally Advanced Non-Small Cell Lung Cancer
Zhi S. Zheng, China

P2.01-079: A Phase I Study Comparing PF-06439535 (A Potential Biosimilar) with Bevacizumab
Beverly Knight, USA

P2.01-080: Pemetrexed, Carboplatin and Bevacizumab in Patients with Non-Squamous NSCLC without or with Activating EGFR Mutation (CJLSG0909/0910)
Tomoki Kimura, Japan

P2.01 TREATMENT OF ADVANCED DISEASE – NSCLC – NEW TARGETS

P2.01-081: Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies
Jody Chuang, USA

P2.01-082: Pathological Response with Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use in Advanced Non-Small Cell Lung Cancer
Pranshu Mohindra, USA

P2.01-083: Prognostic Significance of CK19mRNA Positive Cells in the Peripheral Blood of Patients with Advanced Non Small Cell Lung Cancer (NSCLC)
Athanasios Kotsakis, Greece

P2.01-084: Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer
Jeffrey A. Bacha, Canada

P2.01-085: Abemaciclib in Combination with Single Agent Options in Stage IV NSCLC, a Phase 1b Study
Karen Kelly, USA

P2.01 TREATMENT OF ADVANCED DISEASE – TRIALS IN PROGRESS

P2.01-086: Ceritinib in ALK+ NSCLC Metastatic to Brain and/or Leptomeninges: The ASCEND-7 Study
Laura Q. Chow, USA

P2.01-087: A Phase 1 Trial Combining Plinabulin and Nivolumab for Metastatic Squamous NSCLC
Shihfan Yeh, USA

P2.01-088: nab-Paclitaxel + Carboplatin for Elderly Patients with Advanced NSCLC (ABOUND.70+)
Corey J. Langer, USA
P2.01-089: A Phase 1b/2 Randomized Study of PEGPH20 in Combination with Docetaxel in Hyaluronan High NSCLC Patients Treated with Platinum Chemotherapy  
Chandra P. Belani, USA

P2.01-090: A Phase 2, Single Arm Study of Lucitanib in Patients with Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF-Related Genetic Changes  
David R. Spigel, USA

P2.01-091: Multicenter, Randomized, Double-Blind Study of Erlotinib plus Ramucirumab or Placebo in Patients with EGFR Mutation-Positive Metastatic NSCLC  
Edward B. Garon, USA

P2.01-092: A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously Treated Metastatic Non-Squamous, Non-Small Cell Lung Cancer  
Edward B. Garon, USA

P2.01-093: A Phase III Study of Radiosurgery with TTFIELDS for 1-10 Brain Metastases from NSCLC  
Minesh P. Mehta, USA

P2.01-094: Phase II Trial of Tepotinib/Gefitinib vs Cisplatin/Pemetrexed in T790M-/c-Met+ NSCLC  
Yi-Long Wu, China

P2.01-095: nab-Paclitaxel/Carboplatin Followed By nab-Paclitaxel for NSCLC PS 2 (ABOUND.PS2)  
Ajeet Gajra, USA

P2.01-096: Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced ns-NSCLC  
Jonathan W. Goldman, USA

P2.01-097: Phase 3 Study of Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ NSCLC  
Tony Mok, Hong Kong

P2.01-098: Addition of Custirsen, a Clusterin Inhibitor, to Docetaxel in Stage IV Non-Small Cell Lung Cancer (NSCLC): The ENSPIRITTM Phase 3 Trial  
Joachim Von Pawel, Germany

P2.01-099: nab-Paclitaxel as Maintenance Therapy in Patients with Squamous Cell NSCLC (ABOUND.sqm)  
David R. Spigel, USA

P2.01-100: Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)  
Keunchil Park, South Korea
P2.01-101: Randomized Phase 3 Trial of Docetaxel+Plinabulin Compared to Docetaxel in Advanced Non-Small Cell Lung Cancer with at Least 1 Large Lung Lesion
Lyudmila Bazhenova, USA

P2.01-102: Phase I Study of Inhaled 5-Azacytidine in Patients with Advanced NSCLC
Emrullah Yilmaz, USA

P2.02 TREATMENT OF LOCALIZED DISEASE NSCLC

P2.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – QUALITY/PROGNOSIS/SURVIVAL

P2.02-001: Predictors of Occult Nodal Metastasis in Clinical Stage I NSCLC Staged by FDG-PET/CT
Kaoru Kaseda, Japan

P2.02-002: Impact of Multiple Cancer Treatment History on Outcome in Patients with Surgically Resected Non-Small Cell Lung Cancer
Masaki Anraku, Japan

P2.02-003: Blood Loss Volume During Surgery Is a Significant Adverse Prognostic Factor in Patients with Stage I to IIIA Resected NSCLC
Wenhua Liang, China

P2.02-004: Clinicopathological Features and Outcomes of AAH, AIS and MIA in Resected Lung Adenocarcinoma
Hironori Ishida, Japan

P2.02-005: Precise Prediction of 5-Year Survival of Lung Cancer Patients after Radical Surgery
Oleg Kshivets, Russia

P2.02-006: Development of the New Photodynamic Therapy for Peripheral Type Lung Cancer
Keishi Ohtani, Japan

P2.02-007: Correlation Between Histological Invasiveness and CT Value in Pure GGNs
Akihiko Kitami, Japan

P2.02-008: Planning the Optimal Patient Pathway in the Diagnosis and Staging of Suspected Lung Cancer; What Infrastructure Is Needed?
Haider Al-Najjar, United Kingdom

P2.02-009: Expected Variability of C-Reactive Protein after Pulmonary Resections: Which Factors Are Associated with Their Normal Variation?
Ricardo M. Terra, Brazil

P2.02-010: Pathological Examination of Primary Lung Adenocarcinoma Cases That Were Positive for Intraoperative Pleural Effusion (E1(+), M1a)
Shunta Ishihara, Japan

P2.02-011: Optimal Strategy to Prevent Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer. Network Meta-Analysis
Janusz Kowalewski, Poland

P2.02-012: Prediction of Postoperative Pulmonary Function Using CT Volumetry
Masayuki Hashimoto, Japan

P2.02-013: Strategy of Management for Synchronous Pure GGOs Detected in Patients Undergoing Resection for Primary NSCLC
Chenyang Dai, China

P2.02-014: Cross-Sectional Study on Surgical Treatment Patterns of 1927 Stage I-IIla NSCLC Patients from 11 Medical Centers in China in 2013
Jian Zhou, China

P2.02-015: Prognostic Significance of Histologic Subtype in Stage I Non-Small Cell Lung Cancer
Youngkyu Moon, South Korea

P2.02-016: A New Strategy for Preoperative-Management of Patients with Lung Cancer with Chronic Obstructive Pulmonary Disease (COPD)
Jitsuo Usuda, Japan

P2.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – SURGERY

P2.02-017: Video-Assisted Mediastinoscopic Lymphadenectomy Decreases the Need for Lymph Node Dissection during Lobectomy in Lung Cancer Patients
Akif Turna, Turkey

P2.02-018: Evaluation of Invasiveness among 3 Methods of Thoracoscopic Lobectomy in Patients with NSCLC: A Favorable Result for Uniportal VATS
Guibin Qiao, China

P2.02-019: Role of Sentinel Node Biopsy in Stage IA NSCLC Surgery
Nenad Ilic, Croatia

P2.02-020: Determining the Location of Early-Stage Lung Cancer Using an Endoscopic Ultrasound Device during VATS Procedure
Takashi Inoue, Japan

P2.02-021: Robotic Pulmonary Resection for Lung Cancer: Analysis of the Learning Curve in a Novel Surgical Program
Wael C. Hanna, Canada

P2.02-022: Short and Long-Term Outcomes of Pneumonectomy for Lung Cancer: 15-Years Experience
Syed S. A. Qadri, United Kingdom

P2.02-023: Robotic Thoracic Surgery for Elderly Patients with Non-Small Cell Lung Cancer
Ryan T. Hughes, USA

P2.02-024: Simplified Comorbidity Score for Elderly Patients with Primary Lung Cancer Treated by Video-Assisted Thoracoscopic Surgery
Yohei Yurugi, Japan

P2.02-025: The Equivalent Efficacy of Multiple Operations for MPLC and a Single Operation for SPLC
Hao Fu, China

P2.02-026: Mediastinal Lymph Node Metastasis Pattern from Left Upper Lobe Cancer: Results of Bilateral Superior Mediastinal Nodal Dissection
Toshiya Yokota, Japan

P2.02-027: A Study of Segmentectomy for Primary Lung Cancer
Kotaro Mizuno, Japan

P2.02-028: Diagnostic and Therapeutic Benefits of Thoracoscopic Surgery in Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma
Hirohisa Kato, Japan

P2.02-029: Pre-Operative Pulmonary Function Tests (PFT) and Outcomes from Stage I and II Non-Small Cell Lung Cancer (NSCLC) Treated with Surgery
Nabin Khanal, USA

P2.02-030: Bronchoscopic Therapy for Centrally-Located Early Lung Cancers
Taichiro Ishizumi, Japan

P2.02-031: Surgical Management of Bronchial Carcinoid Tumors: A Monocentric Tunisian Experience
Tarek Kilani, Tunisia

P2.02  TREATMENT OF LOCALIZED DISEASE – NSCLC – CHEMOTHERAPY IN EARLY STAGE DISEASE

P2.02-032: Phase II Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) in Surgically Operable Stage I Non-Small Cell Lung Cancer (STARS)
Joe Y. Chang, USA

P2.02-033: Actual Situation of Adjuvant Chemotherapy for NSCLC in Japan
Ryu Nakajima, Japan

P2.02-034: Induction Therapy with Intercalated TKI and Chemotherapy in NSCLC with Activating EGFR Mutation in Stages II-IIIB: NeoIntercal
Frank Griesinger, Germany
Is There an Optimal Time to Initiate Adjuvant Chemotherapy in Order to Predict the Benefit of Survival in Non-Small Cell Lung Cancer?
Xiaoyu Zhai, China

P2.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – RADIATION

Radiation Therapy Alone in cT1-3N0 Lung Cancer Patients Who Are Unfit for Surgery or Stereotactic Ablative Radiation Therapy
Yong Chan Ahn, South Korea

Evaluation of the Dosimetric Characteristics of Salvage Lung SBRT with Image Deformable Registration Technique
Kaile Li, USA

Clinical Evaluations of Odd/Even Respiratory Phases Based Approach for Determining Internal Target Volume in NSCLC Treated with 4D SABR
Xia D. Li, China

Patterns-Of-Care Study of Stereotactic Ablative Radiotherapy for Lung Cancer in Korea
Jae-Sung Kim, South Korea

Clinical Outcome of Fiducial-Less CyberKnife Stereotactic Ablative Body Radiotherapy for Stage I Non-Small Cell Lung Cancer
Inhye Jung, South Korea

Stereotactic Body Radiotherapy (SBRT) or Surgery in Early Stage (I & II) Non Small Cell Lung Cancer (NSCLC)
Hirsh Koyi, Sweden

P2.03 TREATMENT OF LOCOREGIONAL DISEASE NSCLC

Perioperative Cardiac Events in Patients with Coronary Artery Stent Undergoing Lung Resection for Lung Cancer
Takayuki Ibi, Japan

Surgery for Locally Advanced Lung Cancer after Induction Concurrent Chemo-Radiation Therapy
Kazunori Okabe, Japan

Video Assisted Thoracoscopic Anatomical Resection for Non Small Cell Lung Cancer (NSCLC) Is Increasingly Safe
Diego M. Avella, USA

Surgical Outcomes of Locally Advanced Non-Small Cell Lung Cancer Invading Great Vessels and Heart
Byungjoon Park, South Korea

P2.03-005: Surgical Resection after Definitive Chemoradiotherapy
Laura Romero Vielva, Spain

P2.03-006: Survival Rates after Surgery for Stage-3A (N2) Non-Small Cell Lung Cancer with Induction versus Adjuvant Chemotherapy+/-Radiation Therapy
Eric M. Toloza, USA

P2.03-007: Pneumonectomy for Non Small Cell Lung Carcinoma: Pre-Operative Comorbidities and Post-Operative Morbidity Affect Long Term Survival
Mathew A. Vandeusen, USA

P2.03-008: Surgery for Primary Lung Tumors with Histology Other than Non-Small Cell Lung Cancer: A Single Center Experience
Durgatosh Pandey, India

P2.03-009: Single Institutional Experience of the Surgical Treatment of Second Primary Lung Cancer
Hisashi Saji, Japan

P2.03-010: Sleeve, Semsleeve Lobectomy, Segment Pyramidobasalectomy in Patients with Preoperative Contraindication for Pneumonectomy
Fadil Gradica, Albania

P2.03  TREATMENT OF LOCOREGIONAL DISEASE – NSCLC – CHEMORADIATION

P2.03-011: A Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Unresectable Stage III Non-Small Cell Lung Cancer
Greg Durm, USA

P2.03-012: Neoadjuvant Chemoradiotherapy or Chemotherapy Followed by Surgery Is Superior to That Definitive Chemoradiation in Stage IIIA (N2) NSCLC
Xiao-Ling Xu, China

P2.03-013: A Phase II Study of S-1 and Thoracic Irradiation for Elderly Pts with Locally Advanced Non-Small Cell Lung Cancer: Okayama Lung Cancer Study Group
Hiroshi Ueoka, Japan

P2.03-014: Correlation of Response and Prognostic Markers with Survival in Locally Advanced NSCLC Patients Who Have Treated with Neoadjuvant Chemotherapy Ozden Altundag, Turkey

P2.03-015: A Phase II Trial of Individual Trimodality Treatment in Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer: The ZTOG 1202 Study
Yaping Xu, China
P2.03-016: Comparing Outcomes of Neoadjuvant and Adjuvant Chemotherapy in Non-Small Cell Lung Cancer  
Sandhya Sharma, USA

P2.03-017: Pre-Operative Chemotherapy Followed by Surgery for N2 Non-Small Cell Lung Cancer: A 15-Year Experience  
Jonathan D. Spicer, USA

P2.03-018: Tolerability of Re-Irradiation for Locally Recurrent Lung Cancer  
Veronica Finnegan, USA

P2.03-019: A Phase II Multicentre Study of Gefitinib in Combination with Irradiation Followed by Chemotherapy in Patients with Inoperable Stage III NSCLC  
Cecile Le Pechoux, France

P2.03-020: Radical Lung Resection after Curative Chemoradiotherapy for Locally Advanced Lung Cancer  
Motohiro Yamashita, Japan

P2.03 TREATMENT OF LOCORREGIONAL DISEASE – NSCLC – RADIATION

P2.03-021: Impact of Radiation on Recurrence Patterns and Survival for Patients Undergoing Lobectomy for Stage IIIA-pN2 Non-Small Cell Lung Cancer  
Chi-Fu J. Yang, USA

P2.03-022: Is the Radiosensitivity of the Tumour Related to That of the Lung? A CT-Based Response Analysis of Both  
Dirk De Ruysscher, Belgium

P2.03-023: In-Field Nodal Relapse after Irradiation for Locally Advanced Non-Small-Cell Lung Cancer: Is There a Dose-Effect Relationship?  
Dirk De Ruysscher, Belgium

P2.03-024: PORT-First Strategy After Surgery in Patients with IIIA-N2 Non-Small Cell Lung Cancer  
O Kyu Noh, South Korea

P2.03-025: Predictors of Relapse and Evaluation of Post-Operative Radiotherapy in Patients with Resected Stage III (N2) Non-Small Cell Lung Cancer  
William Breen, USA

P2.03-026: Assessing the Risk of Cardiac Toxicity with Esophageal-Sparing Intensity Modulated Radiotherapy for Locally Advanced Lung Cancers  
Jeremy Ruben, Australia

P2.03-027: Predicting the Effect of 7-Days-A-Week Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer Based on Clinicopathological Features  
Rafal Suwinski, Poland
P2.03-028: Functional Lung Imaging with Perfusion SPECT/CT Improves Prediction of Radiation Pneumonitis
Jing Zeng, USA

P2.03-029: SBRT for Localized Central NSCLC Conventional Radiation Failures; Recurrent Laryngeal Nerve Paralysis Is a Novel Toxicity
Brian Collins, USA

P2.03-030: Adjuvant Radiation Therapy Improves Survival in Pathological Stage IIIA N2 Non-Small Cell Lung Cancer Patients Staged with PET
Mo Mo Tin, Australia

P2.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC – OTHER

P2.03-031: Subgroup Analysis of East Asian Patients in the Phase III PROCLAIM Trial
Luhua (Jingbo) Wang, China

P2.03-032: Prognostic Impact of EGFR and KRAS Mutations in Patients with Lung Adenocarcinoma Treated with Definitive Radiation Therapy
Andreas Rimner, USA

P2.03-033: 18FDG-PET/CT Improves Lung Cancer Staging and Treatment Selection Accuracy
Margarita Majem, Spain

P2.03-034: Association of EGFR Mutation Status with Treatment Outcome in Stage III Non-small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy
Shi Feng Nyaw, Hong Kong

P2.03-035: Impact of Lymph Node Involvement on Survival in Patients with Completely Resected Pulmonary Squamous Cell Carcinoma
Yujin Kudo, Japan

P2.03-036: Primary Pulmonary Large Cell Carcinoma with Syncytiotrophoblastic Aspect: Report of a Case
Luigi Ventura, Italy

P2.03-037: Prognostic Factors in Pathologic N2 Non-Small Cell Lung Cancer
Hye-seon Kim, South Korea

P2.03-038: Whole Tumor Perfusion CT in Patients with NSCLC Treated with Endostar Combined with Concurrent Radiotherapy
Ming Chen, China

P2.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
P2.04-001: EGFR Activating and T790M Resistance Mutation in Plasma exoRNA and cfDNA, Detected with Single-Step Isolation Columns and Targeted Resequencing
Vince O'Neill, Germany

P2.04-002: Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma
Young Wha Koh, South Korea

P2.04-003: Two Methods for Developing in Vitro Erlotinib-Resistant Cell Lines Lead to Distinct RTK Shifts, but Both Result in EMT
Kristine R. Jakobsen, Denmark

P2.04-004: The BIM Deletion Polymorphism in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Ji Yun Lee, South Korea

P2.04-005: Bevacizumab plus Erlotinib in B901L Xenograft Model of EGFR Mut+ NSCLC
Chinami Masuda, Japan

P2.04-006: MiRNA Signature to Assess Sensitivity to FGFR Tyrosine Kinase Inhibitors
Christopher J. Rivard, USA

P2.04-007: In Vitro and in Vivo Efficacy of AZD9291 Is Enhanced by Combination with AZD4547 in EGFR Mutant Lung Cancer Cells
Daniel C. Chan, USA

P2.04-008: IGF1R Expression Is Predictive of Poor Prognosis in EGFR-Mutant Lung Adenocarcinoma
Eunhyang Park, South Korea

P2.04-009: Potential Predictive Markers with Plasma for Re-Challenge with EGFR-TKIs
Tomomi Nakamura, Japan

P2.04-010: 18F-FDG Uptake and CEA between Different EGFR Mutations in Patients with Non-Small Cell Lung Cancer
Xiaorong Dong, China

P2.04-011: Whole-Genome Copy Number Analyses of NSCLC Tumors Reveal Aberrations Associated With EGFR Mutations and May Have Prognostic Impact
Maria M. Bjaanaes, Norway

P2.04-012: The Development of EGFR Mutation Diagnostic Program for NSCLC Patients in Poland (2011-2014)
Joanna Chorostowska-Wynimko, Poland
P2.04-013: Trail Mediates Erlotinib-Induced Apoptosis in EGFR-Mutant Lung Cancer 3D Spheroids
Hyun-Kyung Lee, South Korea

P2.04-014: High Resolution Metabolomics to Discover the Potential Biomarkers in EGFR Mutated Lung Cancer
Sung Yong Lee, South Korea

P2.04-015: Screening EGFR Mutations in NSCLC by Immunohistochemistry
Rania Gaber, Egypt

P2.04-016: Minority Exon 19 Deletions Also Have Major Response of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Eiji Nakajima, Japan

P2.04-017: The Study of a Relationship between Thyroid Transcription Factor-1 Expression and EGFR Mutations in Unselected Thai Patients with NSCLC
Chaiyut Charoentum, Thailand

P2.04-018: Whole Transcriptome Analysis of EGFR Wildtype Non-Small Cell Lung Cancer Patients with Clinical Benefit from Erlotinib
Michael F. Sharpnack, USA

P2.04-019: PD 0332991 Inhibits the Growth of Gefitinib-Resistant Human Lung Cancer Cells in Vitro and in Vivo, When Combined with Gefitinib
Hongyu Liu, China

P2.04-020: Epidermal Growth Factor Receptor (EGFR) Testing among Veterans Diagnosed with Lung Cancer
Michael Kelley, USA

P2.04-021: Predictive Value of Initial Maximal Standardized Uptake Value of 18F-FDG PET/CT in Patients with Lung Adenocarcinoma Treated with Erlotinib
Alper Sevinc, Turkey

P2.04-022: Development of Microfluidic Devices for Rapid, Low-Cost Detection of EGFR Mutations in Cytological Samples from Patients with Lung Cancer
Tetsunari Hase, Japan

P2.04-023: Global Epidemiology of EGFR Mutation in Advanced Non-Small Cell Lung Cancer
Gilberto de Lima Lopes Júnior, Brazil

P2.04-024: NGS Reveals Potential Druggable Targets and Molecular Heterogeneity in EGFR Mutant NSCLC with Acquired Resistance to EGFR TKIs
Byoung Chul Cho, South Korea
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.04-025</td>
<td>Frequency of EGFR Mutation in NSCLC and Its Relationship with Clinicopathological Features: A Multicenter Asmo Trial</td>
<td>Mahmut Gumus, Turkey</td>
</tr>
<tr>
<td>P2.04-026</td>
<td>Second Generation EGFR TKIs Inhibit Tumor Growth in a Chemo-Resistant Squamous Cell Lung Cancer Patient Derived Xenograft Model</td>
<td>Céline Mascaux, Canada</td>
</tr>
<tr>
<td>P2.04-027</td>
<td>Erlotinib Induce miRNA Alterations in T790M EGFR Mutated NSCLC: Preclinical Study</td>
<td>Christian Rolfo, Belgium</td>
</tr>
<tr>
<td>P2.04-028</td>
<td>BIM Deletion Polymorphisms in Hispanic Patients with Non-Small Cell Lung Cancer Who Carriers EGFR Mutations (CLiCaP)</td>
<td>Andrés F. Cardona, Colombia</td>
</tr>
<tr>
<td>P2.04-029</td>
<td>Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology</td>
<td>Tindara Franchina, Italy</td>
</tr>
<tr>
<td>P2.04-030</td>
<td>Activating and Resistance Mutations of EGFR in Peruvian Patients with Metastatic NSCLC</td>
<td>Juan C. Gomez De La Torre, Peru</td>
</tr>
<tr>
<td>P2.04-031</td>
<td>EGFR Mutation Associated with Histologic Subtype According to the IASLC/ATS/ERS Adenocarcinoma Classification: A Meta-Analysis</td>
<td>Yong Song, China</td>
</tr>
<tr>
<td>P2.04-032</td>
<td>Epidemiology and Clinical Outcomes of Epidermal Growth Factor Receptor (EGFR) Mutant Patients at the Brazilian National Cancer Institute (INCA)</td>
<td>Pedro M. Domingues, Brazil</td>
</tr>
<tr>
<td>P2.04-033</td>
<td>Patterns of EGFR Mutations in a Cohort of 395 Patients from a Single Institution in Brazil</td>
<td>Augusto O. Saito, Brazil</td>
</tr>
<tr>
<td>P2.04-034</td>
<td>The Study of EGFR Mutation Specific-Antibody for Detection of EGFR Status in Non-Small Cell Lung Cancer</td>
<td>Chaiyut Charoentum, Thailand</td>
</tr>
<tr>
<td>P2.04-035</td>
<td>Methods for Evaluating Early Response to Erlotinib Treatment Using FDG-PET/CT</td>
<td>Joan Fledelius, Denmark</td>
</tr>
<tr>
<td>P2.04-036</td>
<td>The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas</td>
<td>Young Sik Park, South Korea</td>
</tr>
</tbody>
</table>
P2.04-037: Frequency of EGFR Mutations in NSCLC Patients of the Lung Center of the Philippines
Maria Teresa A. Barzaga, Philippines

P2.04-038: EGFR Mutation Prevalence and Epidemiological Profile of Patients with Metastatic Nonsquamous Non Small Cell Lung Cancer
Clarissa Mathias, Brazil

P2.04-039: A World of EGFR Screening Test
Sébastien Couraud, France

P2.04-040: Impact of Ethnicity on Incidence of Brain Metastasis in Patients with EGFR-Mutant Lung Cancer
Jiexia Zhang, China

P2.04-041: Characterization of EGFR Activating Mutations in Brazilian Patients with Pulmonary Adenocarcinoma
Rafael C. Bitton, Brazil

P2.04-042: Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients with Non-Small Cell Lung Cancer (NSCLC) in a University Hospital in Latin America
Luz F. Sua, Colombia

P2.04-043: A Successful Case in Which Electromagnetic Navigation Bronchoscopy Identified an EGFR Mutation in Small Peripheral Lung Lesions
Jaspal Singh, USA

P2.04  BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING – NOVEL TARGETS

P2.04-044: Analysis of the Intra-Tumor Heterogeneity and Consistency between FGFR1 Gene Amplification and Protein Expression in Squamous Cell Lung Cancer
Joanna Chorostowska-Wynimko, Poland

P2.04-045: Targeting eIF4A1 and eIF4A2 mRNA Helicases in Pulmonary Adenocarcinoma
John Le Quesne, United Kingdom

P2.04-046: Kinome RNAi Screens Identify Essential Genes and Therapeutics In "Driver Negative" Non-Small Cell Lung Cancer
Jihye Kim, USA

P2.04-047: Mitochondrial Activation- A Potential Therapy in Lung Cancer
Nir Peled, Israel

P2.04-048: Analysis of Gene Expression in the Re-Replication Pathway and Selective Blockade with Checkpoint Inhibitors as a Therapeutic Option in NSCLC
Daniela Morales-Espinosa, Spain
P2.04-049: Efficacy of Focal Adhesion Kinase (FAK) Inhibition in RAS Mutant and EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
Hongbin Chen, USA

P2.04-050: Basaloid Squamous Cell Cancers Arising from the Lung: Next Generation Sequencing Reveals PTCH1 Mutations in the Hedgehog Pathway
Bob T. Li, USA

P2.04-051: The Pluripotency Factor Musashi-2 Is a Potential Target for Lung Cancer Therapy
Mary Zhang, USA

P2.04-052: Targeting Oncogenic Eukaryotic Protein Translation in Thoracic Malignancies with Small-Molecule Inhibitors
Zeeshan Ahmad, USA

P2.04-053: Patient-Derived Xenograft Studies Suggest FGFR1 Amplification Is Insufficient to Predict Response to FGFR Inhibitors in Lung SqCC
Shingo Sakashita, Canada

P2.04-054: Targeting DNA Methylation in Chromatin
Simon D. Spivack, USA

P2.04-055: Anti-Glut-1 Antibody as a Novel Therapeutic Modality against Breast and Lung Cancers
George R. Simon, USA

P2.04-056: Analysis of EGFRvIII, PIK3CA, and DDR2 Mutations in Chinese Lung Squamous Cell Carcinoma Patients
Min Li, China

P2.04-057: Targeting PIM Kinase in NSCLC
Martin P. Barr, Ireland

P2.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING – IMMUNOLOGY AND MICROENVIRONMENT

P2.04-058: Neutrophil-Lymphocyte Ratio (NLR) as a Prognostic Marker in Locally Advanced Non-Small Cell Lung Cancer (LANSCLC)
Katherine A. Schrenk, USA

P2.04-059: Structural and Functional Characterization of the Hemolymphangiogenic Microenvironment in Lung Cancer
Federico Quaini, Italy

P2.04-060: Analysis of Lung Microbiome From Patients Undergoing Bronchoscopy
Glen J. Weiss, USA
P2.04-061: Tumor-Associated Fibroblasts Increased Density in Non-Small Cell Lung Cancer Is Mediated by Microenvironment Through β1/FAK Signaling
Noemi Reguart, Spain

P2.04-062: Temporal Programming of Murine Pulmonary Macrophages in N-Nitroso-Tris-(2-Chloroethyl) Urea (NTCU)-Induced Squamous Dysplasia
Lori D. Dwyer-Nield, USA

P2.04-063: Secretome of BM Mesenchymal Stem Cells: An Emerging Player in NSCLC Progression
Maya Gottfried, Israel

P2.04-064: Microenvironmental Factor of Primary Lung Adenocarcinoma Which Predicts the Effectiveness of Chemotherapy in Patients with Recurrences
Haruki Koriyama, Japan

P2.04-065: Distant Bystander Effect of REIC/Dkk-3 Gene Therapy through Immune System Stimulation in a Murine Model of Thoracic Malignancies
Ken Suzawa, Japan

P2.04-066: Programmed Cell Death Ligand 1 (PD-L1) Overexpression and Low Immune Infiltrate Score Correlate with Poor Outcome in Lung Adenocarcinoma
Edwin R. Parra Cuentas, USA

P2.04-067: Clinical Characteristics Associated with PDL1 Positive Status in Resected NSCLC
Georgia Geller, Canada

P2.04-068: PD-L1 Expression in Tumor Infiltrating Immune Cells Determined by Digital Imaging Is Associated with Poor Survival in NSCLC Patients
Bernadette G. Reyna Asuncion, Singapore

P2.04-069: Characteristics and PD-1/PD-L1 Expression of Periphera CD4+CD25+CD127low Treg Cells in Lung Cancer
Hua Shi, China

P2.04-070: Immunological Characterization of PD-L1-Positive Non-Small Cell Lung Cancer Cells
Tomoyuki Igarashi, Japan

P2.04-071: PD-L1 Expression Is Not Associated with Disease-Free Survival in NSCLC Patients Who Underwent Radical Resection
Wenhua Liang, China

P2.04-072: Immunohistochemical PDL1 Expression and Clinicopathological Characteristics in 541 Surgically Resected Non-Small Cell Lung Cancers
Shohei Mori, Japan
P2.04-073: PD-L1 Expression Is Induced by MET in an Erlotinib-Resistant Cell Line with MET Amplification
Christina Demuth, Denmark

P2.04-074: PD-L1 Gene Expression and Total Cell-Free RNA Measured in Blood Positively Differentiate Healthy Individuals from Metastatic NSCLC Patients
Kathleen Danenberg, USA

P2.04-075: Network Analysis of Anti-CTLA4-Induced Regressing Tumours Identifies Novel Synergistic Drug Combinations
Anna K. Nowak, Australia

P2.04-076: Dynamics of Soluble PD-1 during Treatment with EGFR-TKI in Advanced NSCLC Patients
Steffen F. Sorensen, Denmark

P2.04-077: PDL1 Expression in Metastatic Non-Small Cell Lung Cancer Patients from Colombia (CLICaP)
Leonardo Rojas, Colombia

P2.04-078: Functional Characterization of NK Cells in Non-Small Cell Lung Cancer
Oscar Arrieta Rodriguez, Mexico

P2.04-079: Targeting Antigen Presentation by Tumor Infiltrating B Cells to CD4 T Cells in Non-Small Cell Lung Cancer Patient Tumors
Tullia C. Bruno, USA

P2.04-080: Novel Biomarkers for Non Small Cell Lung Cancer (NSCLC)
Lukman Tijani, USA

P2.04-081: The Role of B7-H4-Expressing Macrophage in Malignant Pleural Effusion
Jian an Huang, China

P2.04  BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING – LIQUIED BIOPSYIES

P2.04-082: Diagnostic Value of Survivin-Expressing Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer
Mi-Hyun Kim, South Korea

P2.04-083: Influence of Surgery on EGFR Mutation Abundance among Patients with Early-Stage Non-Small-Cell Lung Cancer
Chengliang Yang, China

P2.04-084: Next-Generation Sequencing with Digital Droplet PCR for Circulating Tumor DNA Quantification in Non-Small-Cell Lung Cancer Patients
Elizabeth Fabre, France
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.04-085</td>
<td>A Comparative Analysis of Cancer Hotspot Mutation Profiles in Circulating Tumour Cells, Circulating Tumour DNA and Matched Primary Lung Tumour</td>
<td>Maria Leung</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>P2.04-086</td>
<td>An Effective In Vivo Liquid Biopsy Tool for High-Yield Isolation of Circulating Tumor Cells</td>
<td>Klaus Luecke</td>
<td>Germany</td>
</tr>
<tr>
<td>P2.04-087</td>
<td>Detection of Mutations from Peripheral Blood in Patients with Non-Small Cell Lung Cancer with Fast Turn-Around</td>
<td>Kathleen Danenberg</td>
<td>USA</td>
</tr>
<tr>
<td>P2.04-088</td>
<td>Surrogate or Not: The Role for Cell Free Circulating DNA in Detecting EGFR Mutations Present in Tumor Tissue</td>
<td>Satya Das</td>
<td>USA</td>
</tr>
<tr>
<td>P2.04-089</td>
<td>Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Tumor DNA During EGFR-Tyrosine Kinase Inhibitor Treatment</td>
<td>In-Jae Oh</td>
<td>South Korea</td>
</tr>
<tr>
<td>P2.04-090</td>
<td>Changes in Circulating Epidermal Growth Factor Receptor (EGFR) during Radiotherapy in Non-Small Cell Lung Cancer (NSCLC) Patients</td>
<td>Feng-Ming (Spring) Kong</td>
<td>USA</td>
</tr>
<tr>
<td>P2.04-091</td>
<td>Digital PCR Analysis of Plasma Cell-Free DNA as a Noninvasive Detection of the Drug Resistance Mechanisms in EGFR Mutant NSCLC</td>
<td>Hidenobu Ishii</td>
<td>Japan</td>
</tr>
<tr>
<td>P2.04-092</td>
<td>Sequencing of Actionable EGFR Mutations from PtDNA in NSCLC: A Feasibility Study of Non-Invasive Analysis of Sensitivity to TKI</td>
<td>Birgitta I. Hiddinga</td>
<td>Belgium</td>
</tr>
<tr>
<td>P2.04-093</td>
<td>Assessment of Clinical Applications of Circulating Tumor DNA in Lung Cancer Using an Enhanced TAm-Seq Platform</td>
<td>Davina Gale</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>P2.04-094</td>
<td>Exosomal MiRNA Analysis of Non-Small Cell Lung Cancer (NSCLC) Liquid Biopsies. Mirror of the Disease Status?: Proof of Concept Study</td>
<td>Christian Rolfo</td>
<td>Belgium</td>
</tr>
<tr>
<td>P2.04-095</td>
<td>Detection of Mutations in Tumor and Blood Samples from Lung Adenocarcinoma Patients Using Two Different Techniques</td>
<td>Jose M. Clavero</td>
<td>Chile</td>
</tr>
<tr>
<td>P2.04-096</td>
<td>Liquid Biopsies in Patients with EGFR Mutated Non-Small Cell Lung Cancer Undergoing Curative Treatment</td>
<td>Eva B. Hansen</td>
<td>Denmark</td>
</tr>
</tbody>
</table>
**P2.04  BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING – OTHER RESISTANCE (NON-EGFR, NON-ALK)**

**P2.04-097:** Vinorelbine Resistance in Lung Cancer; Role of Focal Adhesion Signaling Pathways  
Takao Nakanishi, Japan

**P2.04-098:** Acquired Resistance to Anti-VEGF Therapy in Non-Small Cell Lung Cancer Is Not Associated with Angiogenic Compensation  
Robin E. Frink, USA

**P2.04-099:** Differential Regulation of DNA Repair Genes in Cisplatin Resistant Non-Small Cell Lung Cancer Cells  
Martin P. Barr, Ireland

**P2.04-100:** Platin-Induced ATM Activation in Non-Small Cell Lung Cancer  
Jarrett Moore, Canada

**P2.04-101:** Ganetespib Resistance in KRAS Mutant NSCLC Is Mediated through Reactivation of the RAF/MEK/ERK and PI3K/MTOR Pathways  
Timothy F. Burns, USA

**P2.04-102:** Targeting Inflammatory Mediators to Overcome Intrinsic and Acquired Cisplatin Resistance in Non-Small Cell Lung Cancer  
Anne-Marie Baird, Australia

**P2.04-103:** A Goodpasture Antigen-Binding Protein Kinase Inhibitor to Treat Drug-Resistant Metastatic Lung Cancer  
Juan Saus, Spain

**P2.04-104:** Regulating the Response to Cisplatin in Lung Cancer Cells through the Transcription Factor TCF4: A New Potential Role for Wnt Signaling  
Javier De Castro, Spain

**P2.04-105:** PARP Inhibition Sensitisises ATM Deficient NSCLC Cells to Cisplatin Treatment  
Lars Petersen, Canada

**P2.04-106:** Expression of AEG-1 Associated with Increase of TS Contributes to Chemoresistance of Pemetrexed in Lung Adenocarcinoma  
Chung-Yu Chen, Taiwan

**P2.04-107:** Cofilin-1 as a Biomarker for Non-Small Cell Lung Cancer and a Potential Predictor to Platinum-Based Chemotherapy Resistance  
Juliano Cé Coelho, Brazil

**P2.04-108:** The Role of miR-30c-2* in Clinical Outcome and Drug Resistance in HPV-Infected Non-Small Cell Lung Cancer  
Ya-Wen Cheng, Taiwan
P2.04-109: Epithelial-To-Mesenchymal Transition (EMT) and Acquired Resistance to PI3K- mTOR Inhibition in NSCLC  
Kathy Gately, Ireland

P2.05 PREVENTATION AND TOBACCO CONTROL

P2.05-001: Assessment of Faculty and Staff Smoking Behavior at Total Ban on Smoking in Campus  
Tomoyasu Uno, Japan

P2.05-002: The Risk of Lung Cancer among Women Who Start Smoking as Teenagers  
Malcolm O. Tagbarha, Nigeria

P2.05-003: Poor & Heavy Smokers in Nigeria Face Higher Risk of Lung Cancer DNA Damage  
Emmanuel Odiase, Nigeria

P2.05-004: ETS Exposure Presents a High Risk of Lung Cancer to Restuarant/Bar Workers in Nigeria  
Emmanuel Odiase, Nigeria

P2.05-005: Radon Exposure Prevention of Lung Cancer Policies in Brazil  
Marcelo R. De Sousa Cruz, Brazil

P2.05-006: Meta-Analysis of Radon Indoor Concentrations and Risk of Lung Cancer  
Yula L. Merola, Brazil

P2.05-007: Role of Carbon Monoxide Analyser and NRT in Smoking Cessation  
Sachin Sinha, India

P2.05-008: The Role of Haplotype in 15q25.1 Locus in Lung Cancer Risk: Results of Scanning Chromosome 15  
Christopher I. Amos, USA

P2.05-009: Tobacco Addiction and Perception of Risk of Lung Cancer in Vulnerable Populations  
Jean-François Morere, France

P2.05-010: The Chronic Respiratory Infection as a Background of the Lung Cancers  
Tsutomu Yoshida, Japan

P2.05-011: Presence of Pleural Plaques and/or Asbestosis and the Risk of Lung Cancer in a Crocidolite Asbestos Exposed Population from Western Australia  
Fraser Brims, Australia

P2.06 SCREENING AND EARLY DETECTION
P2.06 SCREENING AND EARLY DETECTION – CT SCREENING PROGRAMS AND IMAGING

P2.06-001: Community-Based Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in the Histoplasmosis Belt of the United States
Emilia A. Porubcin, USA

P2.06-002: Preliminary Results of Early Stage Lung Cancer Detection Using Low-Dose Computed Tomographic Screening
Baohui Han, China

P2.06-003: A System-Wide Lung Cancer Screening Program: First Year Experiences
John C. Ruckdeschel, USA

P2.06-004: Lung Cancer Screening Perceptions in Vermont
Edmund Folefac, USA

P2.06-005: Lung Cancer Risk Perception: Findings from the PAIRS-COPD Study
Angela M. Tod, United Kingdom

P2.06-006: Diagnostic Accuracy of CT-Guided Transthoracic Needle Biopsy for Solitary Pulmonary Nodules
Yong Song, China

P2.06 SCREENING AND EARLY DETECTION – BIOMARKERS

P2.06-007: A miRNA Signature Derived From Independently Replicated Biomarkers of Non-Small Cell Lung Cancer
Christopher J. Rivard, USA

P2.06-008: Diagnostic Yield of Autoantibody Panel for Patients with Ground-Glass Nodules (GGNs) or Solid Nodules in Chinese Population
Caicun Zhou, China

P2.06-009: Oral Glucose Tolerance Test as a Diagnostic Tool in Lung Cancer
Nir Peled, Israel

P2.06-010: Exhaled Biomarkers for Lung Cancer Screening
Pyng Lee, Singapore

P2.06-011: Periostin Investigational Use Only Automated Immunoassay for Abbott ARCHITECT®
Philip M. Hemken, USA

P2.06-012: A Model Incorporating Clinical, Radiographic, and Biomarker Characteristics Predicts Malignancy in Indeterminate Pulmonary Nodules
Jeffrey A. Borgia, USA
P2.06-013: Verification of the Biomarker Candidates for Non-Small-Cell Lung Cancer Using a Targeted Proteomics Approach
Yeoun Jin Kim, Luxembourg

P2.06 SCREENING AND EARLY DETECTION – RISK, HEALTH CARE DELIVERY, MISCELLANEOUS, CASE REPORTS AND SERIES

P2.06-014: A Czech Page in the Lung Cancer Multiplicity
Teodor Horvath, Czech Republic

P2.06-015: Detecting Obstructive Lung Diseases with Aerosol Breath Test: A Non-Invasive Diagnostic Method Using Fractal Analysis and SVM Classification
Jinxiang Xi, USA

P2.06-016: An Epidemiological Study on Detection of Chronic Obstructive Pulmonary Diseases and Lung Cancer by Regional Lung Cancer Mass Screening
Takehiko Fujisawa, Japan

P2.06-017: Incidental Detection of Lung Cancer by Pre-Operative Evaluation, a Series of 6 Cases
Deniz Dogan, Turkey

P2.06-018: Health Disparities Assessment in a Newly Established Lung Cancer Screening Program
Mary Pasquinelli, USA

P2.06-019: Prognosis of Lung Cancer Patients Diagnosed with National Health Surveillance
Chun Sung Byun, South Korea

P2.06-020: Comparison of Cytological Diagnosis Between Solitary and Semi-Solitary Lung Nodules in Biopsy Samples: Experience from a Single Academic Center
Qing Kay K. Li, USA

P2.06 SCREENING AND EARLY DETECTION – DIAGNOSTIC WORKUP

P2.06-021: Analysis of Autofluorescence Bronchoscopy Used for Characterisation and Identification of Bronchopulmonary Cancer
Baohui Han, China

P2.06-022: Multiple Primary Malignancies - A Retrospective Analysis
Anna Romaszko, Poland

P2.06-023: A Complete Thoracic Navigation System to Allow for Nodal and Parenchymal Molecular Assessment in NSCLC: A Prospective Human Study
Jason Akulian, USA

P2.06-024: Study on the Clinical Application of CT-Guided Percutaneous Lung Biopsy
Feng Long, China
New PET/CT Criterion for Nodal Staging in Lung Cancer: Area of SUV ≥ 2.5 / Lymph Node Area
Kazuhiro Imai, Japan

Advanced Bronchoscopies for Diagnosing Precancerous or Cancerous Lesions: A Meta-Analysis
Jianrong Zhang, China

P2.06 SCREENING AND EARLY DETECTION – PROGNOSTIC MARKERS

Pleural Fluid Reactive Oxygen Species Modulator 1 (Romo1) as a Diagnostic and Prognostic Marker in Lung Cancer Patients with Malignant Effusion
Seung Hyeun Lee, South Korea

 Accumulation of 18F-FDG Might Predict the Survival of Early-Stage Lung Cancer Patients
Masashi Yanada, Japan

Risk Factors of Brain Metastases in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
Qin Zhang, China

P2.07 SMALL CELL LUNG CANCER

CK2α Is Highly Expressed and Could Represent a Suitable Therapeutic Target in Small Cell Lung Cancer
Zhilong Zhao, China

Effects of Eribulin and Radiation on a Panel of Small Cell Lung Cancer (SCLC) Cell Lines
Barbara Helfrich, USA

Attempt to Validate Drug Repositioning for Metastatic Small Cell Lung Cancer (SCLC) Therapy Identifies Statins Associated with Survival Benefit
Zoltan Lohinai, Hungary

The Relationship between UGT1A1 Gene Polymorphism and Irinotecan Effect on ED-SCLC
Yuan Chen, China

P2.07 SMALL CELL LUNG CANCER – EXTENSIVE DISEASE

AVE plus Valproate for Refractory/Relapsing SCLC: A Phase II Study by the ELCWP
Thierry Berghmans, Belgium
P2.07-006: Study on Feasibility of Hippocampal Avoidance Prophylactic Cranial Irradiation
Mao Zhang, China

P2.07-007: Prophylactic Cranial Irradiation for Extensive Stage Small Cell Lung Cancer
Yu Yang Soon, Singapore

P2.07-008: CTC 11-001: Phi Study of Carfilzomib (C) + Irinotecan (I) in Relapsed, Irinotecan Sensitive Solid Tumors
Susanne M. Arnold, USA

P2.07-009: Cisplatin Combined with Irinotecan or Etoposide for Untreated Extensive Stage Small Cell Lung Cancer
Yuankai Shi, China

P2.07-010: Alisertib (MLN8237)+Paclitaxel versus Placebo+Paclitaxel for Relapsed SCLC
Taofeek K. Owonikoko, USA

P2.07-011: Maintenance with Lanreotide in SCLC Patients, Expressing Somatostatine Receptors, after Response to First Line Therapy
Francesca La Russa, Italy

P2.07 - SMALL CELL LUNG CANCER – LIMITED DISEASE

P2.07-012: Accelerated Hypofractionated Radiotherapy and Concurrent Etoposide / Cisplatin in Patients with Limited-Disease SCLC (LD-SCLC)
Sherif Abdelwahab, Egypt

P2.07-013: Medically Inoperable Early Stage Small Cell Lung Cancer: Patterns of Failure after SBRT
Gregory M.M. Videtic, USA

P2.07-014: Does Prophylactic Cranial Irradiation Improve Overall Survival of Elderly Patients with Limited-Stage Small Cell Lung Cancer?
Ritsuko U. Komaki, USA

P2.07-015: Pattern of Failure after Definitive Radiotherapy for Small Cell Lung Cancer
Siri S. Rasmussen, Denmark

P2.07 - SMALL CELL LUNG CANCER – PROGNOSIS, EPIDEMIOLOGY AND OTHER

P2.07-016: Prognostic Impact of Bone Metastases in Small Cell Lung Carcinoma
Konstantinos Syrigos, Greece

P2.07-017: Body Composition Analysis Using Computed Tomography in Patients with Small Cell Lung Cancer
Eun Young Kim, South Korea
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors &amp; Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.07-018</td>
<td>The Association of Hyponatremia with the Prognosis of Patients with SCLC</td>
<td>Kong Yue, China</td>
</tr>
<tr>
<td>P2.08</td>
<td>THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES</td>
<td></td>
</tr>
<tr>
<td>P2.08-001</td>
<td>A Randomized, Placebo-Controlled Study of Amatuximab in Combination with Pemetrexed and Cisplatin (P/C) in Subjects with Pleural Mesothelioma</td>
<td>Bruce A. Wallin, USA</td>
</tr>
<tr>
<td>P2.08-002</td>
<td>Germline BAP1 Mutation Is Associated with a Significant Increased Survival and Multiple Cancer in Mesothelioma Patients</td>
<td>Francine Baumann, USA</td>
</tr>
<tr>
<td>P2.08-003</td>
<td>MDM2 Inhibitor plus rhAPO2L/TRAIL: A Promising Strategy for Malignant Pleural Mesothelioma Treatment</td>
<td>Giulia Pasello, Italy</td>
</tr>
<tr>
<td>P2.08-004</td>
<td>Healthcare Professional Perceptions of Chemotherapy in Treatment of Malignant Pleural Mesothelioma (MPM)</td>
<td>Steven Kao, Australia</td>
</tr>
<tr>
<td>P2.08-005</td>
<td>Vinorelbine as Second or Third-Line Therapy in Pemetrexed-Pretreated Malignant Pleural Mesothelioma (MPM) Patients</td>
<td>Giovanni L. Ceresoli, Italy</td>
</tr>
<tr>
<td>P2.08-006</td>
<td>The JmjC Family of Lysine Demethylases Are Overexpressed and Potential Therapeutic Targets in Malignant Pleural Mesothelioma</td>
<td>Steven G. Gray, Ireland</td>
</tr>
<tr>
<td>P2.08-007</td>
<td>The Efficacy and Safety of Re-Challenge Platinum plus Pemetrexed Combination Therapy for Recurrent Malignant Pleural Mesothelioma</td>
<td>Mariko Morishita, Japan</td>
</tr>
<tr>
<td>P2.08-008</td>
<td>A Phase 1 Dose Escalation Study of VS-5584, a PI3K/MTOR Inhibitor, Administered with VS-6063, a Focal Adhesion Kinase Inhibitor, in Mesothelioma</td>
<td>Joanna Horobin, USA</td>
</tr>
<tr>
<td>P2.08-009</td>
<td>Malignant Pleural Mesothelioma: A Retrospective Analysis of Clinicopathological and Survival Data in Egyptian Patients</td>
<td>Ahmed Nagy, Egypt</td>
</tr>
<tr>
<td>P2.08-010</td>
<td>Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma</td>
<td>Hedy Lee Kindler, USA</td>
</tr>
<tr>
<td>Paper Number</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>-------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>P2.08-011</td>
<td>Surgical Cytoreduction and HITHOC for Malignant Pleural Tumors</td>
<td>Michael Ried, Germany</td>
</tr>
<tr>
<td>P2.08-012</td>
<td>Differentiation of Mesothelioma from Lung Cancer and Healthy</td>
<td>Salih A. Emri, Turkey</td>
</tr>
<tr>
<td></td>
<td>Individuals Using Human Serum by ATR-FTIR Spectroscopy Coupled with</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chemometrics</td>
<td></td>
</tr>
<tr>
<td>P2.08-013</td>
<td>A Phase II Trial of TTFields with Chemotherapy for First Line</td>
<td>Uri Weinberg, Switzerland</td>
</tr>
<tr>
<td></td>
<td>Treatment of Malignant Mesothelioma</td>
<td></td>
</tr>
<tr>
<td>P2.08-014</td>
<td>Therapeutic Effectiveness of MET/RON Small Molecule Inhibitor BMS-777607 on Cell Viability of Human Malignant Pleural Mesothelioma Cell Lines</td>
<td>Steven G. Gray, Ireland</td>
</tr>
<tr>
<td>P2.08-015</td>
<td>The Relationship between the Cost of Treatment and Prognosis in</td>
<td>Guntulu Ak, Turkey</td>
</tr>
<tr>
<td></td>
<td>Malignant Mesothelioma in Turkey</td>
<td></td>
</tr>
<tr>
<td>P2.08-016</td>
<td>Pleural Mesothelioma Incidence in Sweden: No Ccrease in Sight</td>
<td>Gunnar N. Hillerdal, Sweden</td>
</tr>
</tbody>
</table>

**P2.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES – OTHER THORACIC MALIGNANCIES**

<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.08-017</td>
<td>Chest Wall Soft Tissue Sarcomas: Impact of Adjuvant Radiation Therapy Following Surgical Resection</td>
<td>Adnan M. Al-Ayoubi, USA</td>
</tr>
<tr>
<td>P2.08-018</td>
<td>The Impact of the Resection Margin on Recurrence and Survival in</td>
<td>Severin Schmid, Germany</td>
</tr>
<tr>
<td></td>
<td>Bronchopulmonary Carcinoids</td>
<td></td>
</tr>
<tr>
<td>P2.08-019</td>
<td>Accuracy of Percutaneous Closed Pleural Biopsy in Thoracic Malignancies</td>
<td>Renata Báez-Saldaña, Mexico</td>
</tr>
<tr>
<td>P2.08-020</td>
<td>Percutaneous Cryoablation for Pulmonary Metastasis of Soft Tissue and Bone Sarcomas</td>
<td>Keisuke Asakura, Japan</td>
</tr>
<tr>
<td>P2.08-021</td>
<td>Radionuclide Therapy with Meta-Iodo-Benzyl-Guanidine (MIBG) for Patients with MIBG Avid Pulmonary Carcinoid Tumors</td>
<td>Robert A. Ramirez, USA</td>
</tr>
<tr>
<td>P2.08-022</td>
<td>Pulmonary Resection of Metastatic Renal Cell Carcinoma</td>
<td>Olga Lebedieva, Ukraine</td>
</tr>
<tr>
<td>Paper ID</td>
<td>Title</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>P2.08-023</td>
<td>Aberrant Neuroendocrine Lung Tumor Nomenclature in Daily Practice, How Common Is It? Jules L. Derks, Netherlands</td>
<td></td>
</tr>
<tr>
<td>P2.08-024</td>
<td>CT Findings of Early Pleural Mesothelioma and Benign Asbestos Pleural Effusion Katsuya Kato, Japan</td>
<td></td>
</tr>
<tr>
<td>P2.08-025</td>
<td>Contributing Factors to the Outcome of Primary Malignant Chest Wall Tumors Abdelrahman M. Abdelrahman, Egypt</td>
<td></td>
</tr>
<tr>
<td>P2.08-026</td>
<td>Molecular Markers of Resected Esophageal Squamous Cell Cancer and Its Correlation with Clinical Outcome Yaping Xu, China</td>
<td></td>
</tr>
<tr>
<td>P2.08-027</td>
<td>Investigation for the Optimum Resectable Pathological Size of Small Solitary Metastasis from Colorectal Cancers Yukinori Sakao, Japan</td>
<td></td>
</tr>
<tr>
<td>P2.08-028</td>
<td>Mediastinal Primary Malignant Germ Cell Tumor - Analysis of Prognostic Factors for Patients' Survival. Single Institution Experience Elzbieta Nowara, Poland</td>
<td></td>
</tr>
<tr>
<td>P2.08-029</td>
<td>Stereotactic Ablative Radiotherapy (SABR) for Pulmonary Oligometastases and Oligoprogression Patrick Cheung, Canada</td>
<td></td>
</tr>
</tbody>
</table>

**P2.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES - THYMOMA**

<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2.08-030</td>
<td>Sunitinib in Patients with Advanced Thymoma and Thymic Carcinoma. Retrospective Analysis from RYTHMIC Database Jordi Remon, France</td>
</tr>
<tr>
<td>P2.08-031</td>
<td>Usefullness of Positron Emission Tomography in Thymic Lesions' Surgery Ioannis Gkiozos, Greece</td>
</tr>
<tr>
<td>P2.08-032</td>
<td>Multimodality Treatment for Advanced Thymoma Ikuo Kamiyama, Japan</td>
</tr>
<tr>
<td>P2.08-033</td>
<td>DNA Methylation on Promotor Region of RASSF1 Gene in Thymic Neuroendocrine Tumor Is Higher than B3 Thymoma and Thymic Squamous Cell Carcinoma Koichiro Kajiura, Japan</td>
</tr>
<tr>
<td>P2.08-034</td>
<td>&quot;Nerve Sparing&quot; Surgery for Invasive Thymomas Pietro Bertoglio, Italy</td>
</tr>
</tbody>
</table>
P2.08-035: Thymoma in Persahabatan Hospital Jakarta, Indonesia 2007 - 2012: An Observational Study
Elisna Syahruddin, Indonesia

P2.09 NURSING AND ALLIED PROFESSIONALS

P2.09-001: Triage Nurse Navigator Implementation: Improvements in NSCLC Resource Utilization
Kelly Zibrik, Canada

P2.09-002: Development of 'Living Well' - A Health and Wellbeing Programme for Thoracic Cancer Patients
Paula Tindale-Paul, United Kingdom

P2.09-003: Identifying Research Questions in Disclosure of Risk of Recurrence following Lung Cancer Surgery Using a Critical Synthesis of the Literature
Matthew Johnson, United Kingdom

P2.09-004: Prospective Audit of Lung Cancer Nurse Specialists Telephone Link Line Call to Surgical Patients 30 Days Post Hospital Discharge
Lavinia Magee, United Kingdom

P2.09-005: Living With Lung Cancer - Preferred Sources of Patient Support and Information: The Papworth Experience
Lavinia Magee, United Kingdom

P2.09-006: A Breathlessness Booklet
Carol A. Davies, United Kingdom

P2.11 PALLIATIVE AND SUPPORTIVE CARE

P2.11-001: The Relationship between Carnitine Pharmacokinetics and Fatigue in Thoracic Cancer Patients Treated with Cisplatin-Containing Chemotherapy
Tatsuhiko Kashii, Japan

P2.11-002: Identifying Relationship between Symptom Burden and Overall Survival in Patients with Advanced Nonsmall Cell Lung Cancer: A Prospective Study
Fatma Özbaki, Turkey

P2.11-003: Changes in Quality of Life Through the Early Intervention by a Palliative Care Team for Patients with Advanced Lung Cancer
Taro Yokoyama, Japan

P2.11-004: Assessment of Pain Management in Cancer Outpatients Who Receive Chemotherapy
Akiko Fujii, Japan

P2.11-005: The Use of Duloxetine in Chemotherapy-Induced Peripheral Neuropathy
P2.11-006: Impact of Different Comorbidities in Clinical and Molecular Characteristics in a Cohort of Non-Small Cell Lung Cancer (NSCLC) Patients (P)
Enric Carcereny, Spain

P2.11-007: Geriatric Oncology and Lung Cancer: Comprehensive Geriatric Assessment (CGA) Aspects Related to Outcomes and Important End-Points
Helano C. Freitas, Brazil

P2.11-008: Association between Heart/Lung Dosimetric Parameters and Subsequent Changes in Quality of Life in Patients Receiving Thoracic Radiotherapy
Lawrence B. Marks, USA

P2.11-009: Depression and Disability in Lung Cancer Patients in a Nigerian Teaching Hospital
Victor Lasebikan, Nigeria

P2.11-010: Predictors of Thromboembolic Events in Patients with Lung Cancer
Bohdan Kadlec, Czech Republic

P2.11-011: Utility of Tolvaptan and Demeclocycline in Addition to Systemic Chemotherapy for the Management of Hyponatraemia in Small Cell Lung Cancer
Robert L. Metcalf, United Kingdom

P2.11-012: A Retrospective Assessment of Mortality of Patients Who Died in the Respiratory Intensive Care Unit with a Diagnosis of Lung Cancer
Nesrin Ocal, Turkey

P2.11-013: Prognostic Factors Associated with Overall Survival in Croatian Patients with Advanced Lung Cancer
Dragan Trivanovic, Croatia

P2.11-014: Tunneled Pleural Catheters Are Safe in the Setting of Chemotherapy and Immune Suppression
Jed A. Gorden, USA

P2.11-015: Factors Related with Reluctance to Treatment in Lung Cancer
Jung Hyun Chang, South Korea